BioNTech, immatics cancer news
The Glioma Actively Personalized Vaccine Consortium (GAPVAC) received €6 million ($7.8 million) in funding from the EU's Framework Programme 7 (FP7) to develop a new class of therapeutic cancer vaccines for brain cancer patients. The project, led by immatics and BioNTech, will use immatics' antigen discovery platform XPRESIDENT to generate tumor-associated peptides that are selected based on transcriptomic and peptidomic analysis to be most suitable for each individual patient. BioNTech will contribute glioblastoma-expressed tumor-associated antigens. immatics and BioNTech will then identify immunogenic tumor mutations and generate a blueprint for a personalized vaccine that will include patient-specific tumor mutated peptides. A Phase I trial in up to 30 newly diagnosed glioblastoma patients is slated to begin early next year. Under the project, BCN Peptides S.A. (Barcelona, Spain) will manufacture the peptides for clinical use. ...